Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MoonLake Immunotherapeutics ( (MLTX) ) has issued an update.
On February 20, 2026, MoonLake Immunotherapeutics amended its loan and security agreement with Hercules Capital, expanding a senior secured credit facility to six tranches totaling up to $500 million and drawing an additional $25 million. The amended structure leaves up to $400 million of non-dilutive debt available, largely contingent on key clinical and regulatory milestones for sonelokimab in hidradenitis suppurativa and psoriatic arthritis, and introduces a conditional revenue covenant tied to future product sales.
All obligations under the facility are secured by substantially all of MoonLake’s and its material subsidiaries’ assets, including intellectual property, and the loans feature no scheduled amortization with principal due at maturity. The financing package bolsters MoonLake’s balance sheet alongside its existing cash, cash equivalents and short-term marketable debt securities of $394 million as of December 31, 2025, supporting the costly late-stage development and potential commercialization of sonelokimab.
On February 18, 2026, board member Simon Sturge notified MoonLake he would resign effective February 28, 2026, after which the board will shrink from six to five directors. The company said his departure was not due to any disagreement on operations or policies, and it appointed CEO Jorge Santos da Silva as interim chair and director Spike Loy as lead independent director from the same date, signaling continuity in governance during a pivotal clinical phase.
On February 22, 2026, MoonLake reported positive topline results from its Phase 2 S-OLARIS trial of sonelokimab in axial spondyloarthritis, where 81% of treated patients achieved an ASAS40 response at week 12. Additional clinical, imaging and biomarker data, including SPARCC MRI and PET measures of inflammation and osteoblast activity, indicated rapid, deep-tissue effects and a safety profile consistent with prior trials, reinforcing the drug’s potential to modify disease pathways in axial spondyloarthritis.
The same day, the company released financial results for the fourth quarter and full year 2025, posting research and development expenses of $56 million and general and administrative expenses of $9.2 million for the quarter. MoonLake said its year-end cash and marketable securities, together with recent equity proceeds and the amended Hercules facility, are expected to fund operations into the second half of 2027, underpinning multiple upcoming data readouts and regulatory steps in its late-stage pipeline.
MoonLake also confirmed it would hold an Investor Day webcast on February 23, 2026 to present the S-OLARIS data, discuss outcomes of a recent Type B FDA meeting for hidradenitis suppurativa and outline its biologics license application plans. Management intends to share interim Phase 3 hidradenitis suppurativa data, adolescent trial results and detail 2026 catalysts, including Phase 3 readouts in psoriatic arthritis and palmo-plantar pustulosis program plans, indicating an intense news flow that could influence investor expectations and partner interest.
The most recent analyst rating on (MLTX) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on MoonLake Immunotherapeutics stock, see the MLTX Stock Forecast page.
Spark’s Take on MLTX Stock
According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.
The score is held back primarily by accelerating losses and significant ongoing cash burn despite a solid balance sheet. Technicals are mixed—improving in the short term but still weak longer term. Offsetting these risks, corporate updates were meaningfully positive, including FDA feedback that de-risks the sonelokimab regulatory path and supportive clinical trial readouts.
To see Spark’s full report on MLTX stock, click here.
More about MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a Nanobody that inhibits IL-17A and IL-17F to treat inflammatory diseases. The company is focused on indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and other immunology-driven conditions, positioning itself in competitive autoimmune and rheumatology markets.
Sonelokimab has generated positive Phase 2 and Phase 3 data across five indications, underscoring MoonLake’s strategy to leverage a single advanced biologic platform across multiple high-burden inflammatory diseases. With a growing late-stage pipeline and a capital structure combining equity and non-dilutive debt, the company is aiming to advance toward commercialization in the U.S. and other major markets.
Average Trading Volume: 2,255,049
Technical Sentiment Signal: Sell
Current Market Cap: $1.32B
See more data about MLTX stock on TipRanks’ Stock Analysis page.